Overview
Distalmotion provides a surgical robotics system called Dexter used in minimally invasive surgery. It sells the robotic platform to hospitals and surgical centers, aiming to integrate into existing laparoscopic workflows so surgeons can switch between robotic and traditional laparoscopy from an ergonomic console. Dexter is designed as an open-platform, mobile system that supports on-demand robotic assistance without needing a dedicated operating room, enabling seamless collaboration between robotic precision and conventional techniques. This approach differentiates Distalmotion from competitors by prioritizing ease of integration, mobility, and flexibility over building a closed, room-locked robot. The company's goal is to make robotic surgery more accessible, addressing barriers like complexity, cost, and workflow disruption to improve outcomes in general surgery, gynecology, and urology.
Work here?Claim your company
Simplify's take
What believers are saying
- Cypress Surgery Center and Surgery Partners sites show DEXTER traction in U.S. ASCs.
- June 2026 gynecology clearance broadened revenue opportunities beyond hernia and cholecystectomy.
- October 2026 financing supports sales hiring, instrument development, and deeper U.S. penetration.
What critics are saying
- Intuitive, Medtronic, CMR Surgical, and J&J Ottava pressure Distalmotion's ASC wedge immediately.
- DEXTER still lacks a broad installed base, so hospital buyers can delay purchases through 2027.
- If U.S. ASC adoption stalls, the $70 million debt facility tightens financing and growth.
What makes Distalmotion unique
- Dexter fits existing ORs and switches between robotic and laparoscopic techniques.
- August 2026 FDA clearance gave Distalmotion the top four outpatient soft-tissue procedures.
- Perceptive Advisors funded up to $70 million for ASC expansion on October 21, 2026.
Help us improve and share your feedback! Did you find this helpful?